newsfilter
← Latest News
GlobeNewswire·

Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13

  • Capricor Therapeutics (NASDAQ: CAPR) will release financial results for the second quarter ended June 30, 2026, after the market close on Thursday, August 13, 2026.
  • Management will host a conference call & webcast at 4:30 p.m. ET on August 13, 2026, using toll-free number 1-800-717-1738 or international number 1-646-307-1865 with Conference ID 91880.
  • A replay of the webcast will be available in the Investors section of the company website at www.capricor.com shortly after the event concludes.
  • The company's lead product candidate, Deramiocel, is a late-stage allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy (DMD) designed to preserve cardiac & skeletal muscle function.
  • Capricor is also advancing its StealthX™ exosome platform for targeted delivery of oligonucleotides, proteins, & small-molecule therapeutics.
  • The press release includes a cautionary note regarding forward-looking statements related to clinical trial results, regulatory filings, financial position, & ongoing litigation with Nippon Shinyaku Co., Ltd. & NS Pharma, Inc.
  • Deramiocel & the StealthX™ vaccine remain investigational candidates & have not received approval for commercial use in any indication.